Lancet Respiratory Medicine

Journal Title：Lancet Respiratory Medicine

The Lancet Respiratory Medicine delivers comprehensive, clinically-focused coverage on all areas of respiratory medicine and critical care, including but not limited to: COPD, asthma, cystic fibrosis, IPF, pneumonia, influenza, tuberculosis, sarcoidosis, pulmonary hypertension, sleep medicine, respiratory infections, pulmonary vascular disease, lung cancer, tobacco control, thoracic and reconstructive surgery, mesothelioma, and palliative medicine. Continuing in The Lancet's tradition of publishing high-impact content that influences medical practice, each monthly issue of The Lancet Respiratory Medicine contains Original Research, Reviews, Personal Views, Comments, and News.

The Lancet Respiratory Medicine is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Original Research is fast-tracked to publication within 8 weeks of submission (on average) and published Online First on www.thelancet.com before appearing in print.

Now indexed in PubMed, Journal Citation Reports®, and Scopus, the journal accepts submissions of Original Research, Reviews, Personal Views, and Comments. Visit http://ees.elsevier.com/thelancetrm to learn more about our editorial scope and aims and to submit your manuscript.

Gold or Green Open Access is available for research supported by selected funding agencies with whom Elsevier has an agreement. The journal is also freely available to readers in low-to-middle-income countries via the HINARI programme or via IP access at www.thelancet.com.

To find out more about The Lancet Respiratory Medicine, visit www.thelancet.com/respiratory.

《柳叶刀呼吸医学》全面、以临床为重点，涵盖呼吸医学和重症监护的所有领域，包括但不限于：慢性阻塞性肺病、哮喘、囊性纤维化、特发性肺纤维化、肺炎、流感、结核病、结节病、肺动脉高压、睡眠医学、呼吸道感染、肺血管疾病、肺癌、烟草控制、胸外科和重建外科、间皮瘤和姑息医学。《柳叶刀呼吸医学》延续了《柳叶刀》发表影响医学实践的高影响力内容的传统，每月一期，都包含原创研究、评论、个人观点、评论和新闻。

《柳叶刀呼吸医学》经过严格编辑和同行评审，以确保其多样化内容的科学价值和临床相关性。原创研究在提交后 8 周内（平均）即可快速发表，并在 www.thelancet.com 上在线发表，然后才印刷出来。

该期刊现已被 PubMed、Journal Citation Reports® 和 Scopus 收录，接受原创研究、评论、个人观点和意见的投稿。请访问 http://ees.elsevier.com/thelancetrm 详细了解我们的编辑范围和目标，并提交您的稿件。

黄金或绿色开放获取适用于 Elsevier 与之有协议的选定资助机构资助的研究。该期刊还可通过 HINARI 计划或通过 www.thelancet.com 上的 IP 访问免费提供给中低收入国家的读者。

要了解有关《柳叶刀呼吸医学》的更多信息，请访问 www.thelancet.com/respiratory。

Lancet Respiratory Medicine创刊于2013年，由Elsevier Ltd出版商出版，收稿方向涵盖RESPIRATORY SYSTEM - RESPIRATORY SYSTEM全领域，在行业领域中学术影响力很大，属于TOP期刊，国际一流期刊，关注度和专业度非常高，所以对原创文章要求创新性很高，过审难度很高，如果您有志于TOP期刊，建议关注此刊。平均审稿速度 ，影响因子指数38.7，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。